Journal Article

Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers

Datto, Michael, Green, Michelle, Strickler, John H, Previs, Rebecca A, McCall, Shannon J, Spinosa, Daniel, Havrilesky, Laura J, McKinney, Matthew, Broadwater, Gloria, Hubbard, Christopher, Wong, Janice, de Oca Mary Katherine Montes, Watson, Catherine H, Berchuck, Andrew, Strickland, Kyle C

2021

Overview

BackgroundRecent advances in next-generation sequencing have allowed for an increase in molecular tumor profiling.ObjectiveWe sought to assess the actionability and clinical utilization of molecular tumor profiling results obtained via Foundation Medicine tumor sequencing tests in uterine and ovarian cancers.Patients and MethodsWe performed a single-institution retrospective chart review to obtain demographic and clinical information in patients with uterine and ovarian cancer whose tumors were submitted to Foundation Medicine for molecular tumor profiling over a 7-year period. Alterations identified on testing were stratified according to the OncoKB database actionability algorithm. Descriptive statistics were primarily used to analyze the data.ResultsTumors from 185 women with gynecologic cancer were submitted for molecular tumor profiling between 2013 and 2019. The majority of tests (144/185; 78%) were ordered after a diagnosis of recurrence. In 60 (32%), no actionable molecular alteration was identified. Thirteen (7%) identified an alteration that directed to a US Food and Drug Administration-approved therapy in that tumor type, while 112 (61%) had alterations with investigational or hypothetical treatment implications. In patients with any actionable finding, treatment was initiated in 27 (15%) based on these results.ConclusionsThe majority of uterine and ovarian cancers (93%) did not have molecular alterations with corresponding Food and Drug Administration-approved treatments. Even in patients with a potentially actionable alteration, gynecologic oncologists were more likely to choose an alternative therapy. Further investigation is warranted to determine which patients with uterine and ovarian cancer are most likely to benefit from molecular tumor profiling and the ideal timing of testing. The potential to identify effective therapeutic options in a minority of patients needs to be balanced with the current limited clinical applicability of these results in most cases.

• Publisher: Springer Nature B.V
• Subject: FDA approval / Ovarian cancer / Targeted cancer therapy / Tumors / Uterine cancer